Cofactor Genomics, Inc., a clinical-stage company focused on bridging the precision medicine gap through RNA decoding, has announced the appointment of Dr. Howard McLeod, Pharm.D., FASCO, FCCP, to its Advisory Board. Dr. McLeod is a recognized global leader in precision medicine, bringing over 25 years of experience in the biopharmaceutical industry. His expertise covers all aspects of pharmaceutical and regulatory science, with a particular emphasis on oncology, from preclinical to post-market development.
“As we work to onboard our partnered healthcare systems across the U.S. with the recently Medicare-approved OncoPrism, Dr. McLeod’s extensive experience in integrating precision medicine solutions is invaluable,” said Dr. Jarret Glasscock, Cofactor Genomics’ Co-founder and CEO. “Personally, I have long admired Howard’s ability to bridge the gap between precision medicine and patient care, addressing the needs of hospital systems effectively.”
Dr. McLeod remarked, “The progress the Cofactor team has made in developing a product with such significant clinical potential is impressive. I’m excited to help bring precision medicine to the forefront of clinical decision-making, enabling more informed treatment options for cancer patients.”
A veteran in academia, industry, and regulatory affairs, Dr. McLeod has over 25 years of experience leading successful precision medicine initiatives, particularly in oncology. He currently serves as Director of the Center for Precision Medicine & Functional Genomics and is a Professor of Medicine and Biology at Utah Tech University. He has managed all facets of the precision medicine pipeline, including research, clinical trial design, translational development, operations, and regulatory affairs. Additionally, he has been a Board Member or Founder of over a dozen private and public companies and has published more than 600 peer-reviewed papers on precision medicine, pharmacogenomics, and cancer pharmacology in collaboration with major medical centers.
About Cofactor:
Cofactor Genomics is a clinical-stage diagnostics company dedicated to bridging the precision medicine gap by decoding RNA to address major healthcare challenges. The company unlocks RNA’s potential as a transformative health indicator through its PRISM database of patented Health Expression Models (HEMs). These models represent a significant advancement over traditional gene mutation tests, utilizing cutting-edge machine learning and RNA technology to create high-dimensional models of biology, disease, and therapy response.
Cofactor’s innovative RNA modeling has been published in prestigious journals, including The Journal of ImmunoTherapy of Cancer and The Journal of Molecular Diagnostics, and has been recognized as breakthrough research in cancer by Nature Scientific Reports. Cofactor partners with 38 healthcare systems, representing 20% of the U.S. healthcare landscape. Its OncoPrism test is CAP/CLIA-validated and Medicare-approved.
